Argenica (ASX:AGN) provides more proof of traumatic brain injury reduction
More preclinical data showing efficacy on an animal model has Argenica further on the path toward clinical trials for traumatic brain injury.
More preclinical data showing efficacy on an animal model has Argenica further on the path toward clinical trials for traumatic brain injury.
ARG-007 trials will continue unmodified across ten Australian hospitals after no adverse events in the first five patients.
Five patients have now safely been dosed and Argenica marks another milestone in pivotal second phase trials in the battle against stroke.
Argenica’s Liz Dallimore on clinical trials, cerebral tribulations, and dosing its first patient in the battle against stroke.
A first dosing marks the official beginning of Phase 2 clinical trials to prove ARG-007’s efficacy in treating victims of acute ischaemic stroke.
A Pediatric Disease Designation for Argenica’s therapeutic opens the post-clinical way for a priority review and path to market.
More positive Travelan results support progression toward Phase 3 clinical trials and a pivotal FDA registration.
Argenica Thereapeutics have funding to bring its novel drug to reduce brain tissue death after stroke a step closer to approval.
Immuron expect sales to continue as retail pharmacies restock and short-term resident returns approach pre-pandemic levels.